Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Screening period:~* Signed and dated informed consent form (ICF) prior to any study-mandated procedure;~* Male and female participants; 18 years (or year of country specific majority) or older;~* Historical documentation in the participant's medical records on uncontrolled blood pressure despite at least 3 background antihypertensive medications within 1 year before screening visit;~* Treated with at least 3 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit (Visit 1);~* Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 140 mmHg measured by Automated Office Blood Pressure Measurement (AOBPM);~* Women of childbearing potential are eligible only if the following applies:~  * Negative pregnancy test at screening and at baseline (i.e., before randomization);~ * Agreement to undertake pregnancy tests during the study and up to 30 days after randomized study treatment discontinuation;~ * Agreement to use methods of birth control from Screening up to at least 30 days after randomized study treatment discontinuation.~Run-in period (RI):~* Switched to the standardized background antihypertensive therapy at least 4 weeks before the first RI visit;~* Mean trough SiSBP greater than or equal to140 mmHg as measured by AOBPM.~Randomization period:~* Stable dose of the standardized background antihypertensive therapy for at least 1 week before the end of the RI period;~* Mean trough SiSBP greater than or equal to 140 mmHg measured by AOBPM.~Exclusion Criteria:~* Apparent/pseudo Resistant Hypertension (RHT) due to white coat effect, medical inertia, poor therapeutic adherence, or secondary causes of hypertension (except sleep apnea);~* Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and/or Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg as measured by AOBPM at two different timepoints;~* Pregnant or lactating participants;~* Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator (exclusion of participants with significant or potential unstable cardiac disease);~* Severe renal insufficiency;~* Any known factor, disease or clinically relevant medical or surgical conditions that, in the opinion of the investigator, might put the participant at risk, interfere with treatment compliance, study conduct or interpretation of the results.~* Treatment with any medication which may affect blood pressure (BP) and/or treatment with high dose of loop diuretics (i.e., furosemide greater than 80 mg/day, or equivalent dosage of other loop diuretics).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprocitentan 25 mg in Part 1 (double-blind) (Type: EXPERIMENTAL): Participants will receive aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.
- Aprocitentan 12.5 mg in Part 1 (double-blind) (Type: EXPERIMENTAL): Participants will receive aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.
- Placebo in Part 1 (double-blind) (Type: PLACEBO_COMPARATOR): Participants will receive placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.
- Aprocitentan 25 mg in Part 2 (single-blind, single arm) (Type: EXPERIMENTAL): After 4-weeks in the double-blind randomized part (Part 1), participants will received 25 mg aprocitentan, orally, once daily in the morning for 32 weeks.
- Aprocitentan 25 mg in Part 3 (double-blind withdrawal) (Type: EXPERIMENTAL): After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.
- Placebo in Part 3 (double-blind withdrawal) (Type: PLACEBO_COMPARATOR): After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).